oasis 1 oral semaglutide 50 mg obesity nejm 2023 results of #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Oral Semaglutide 25 mg and

Most preclinical studies of GLP-1R agonists to date examine short-term responses, often after a single dose or brief treatment window

medscape.com/viewarticle/997481 Zhou Y, Chen M, Liu L, Chen Z

PlexusDx combines your genetic data with clinical response tracking to refine your diet in real time, so your yogurt choicesand all meal decisionsbecome data-driven rather than guesswork

Step 2: decide later

The report observed the connection in the medical records of over three million people with diabetes and nearly one million taking GLP-1 drugs for weight loss

Safety Profile and Adverse Effects Gastrointestinal effectsnausea, vomiting, diarrheaare the most common and often improve with gradual dose escalation